EMA's CHMP Backs AstraZeneca's Drug For Rare Blood Disorder In Children

  • AstraZeneca Plc AZN said that the European Medicines Agency (EMA) has recommended approving a medicine from its recently acquired Alexion for a rare, deadly blood disorder in children and adolescents aged up to 18 years.
  • Ultomiris has been given a positive opinion for paroxysmal nocturnal hemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows the U.S. approval for adolescents in June.
  • The EMA endorsement includes children with a bodyweight of 10 kg or above and those clinically stable patients after being treated with another Alexion drug, Soliris, for at least the past six months.
  • Ultomiris is an improved version of Alexion's best-selling drug Soliris, which is used against a range of rare immune disorders, including PNH, where the body's immune system attacks its red blood cells, causing anemia and blood clots.
  • Price Action: AZN shares are down 1.55% at $57.33 during the premarket session on the last check Friday.
  • Related content: Benzinga's Full FDA Calendar.
Loading...
Loading...
AZN Logo
AZNAstraZeneca PLC
$74.681.27%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
52.65
Growth
82.07
Quality
61.11
Value
21.38
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...